SCHEMBL4895370

SCHEMBL4895370

Cc1cc(C23CC4CC(CC(C4)C2)C3)c(O)c(S(N)(=O)=O)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
GFER P55789 2/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
RARB P10826 4/20 0.35
RARA P10276 3/20 0.35
RARG P13631 3/20 0.35
CNR2 P34972 2/20 0.34
TP53 P04637 1/20 0.34
CYP3A4 P08684 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
ALOX12 P18054 1/20 0.34
MAPK1 P28482 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4890237 0.86 MEN1 (0.33) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL549445 0.81 MEN1 (0.43) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL27199176 0.80 SELL (0.45) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL3764420 0.77 MEN1 (0.38) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL15771427 0.75 MEN1 (0.39) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL15613285 0.74 ALOX12 (0.37) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL1685213 0.74 ERN1 (0.53) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL27448236 0.73 ACHE (0.45) KDM4EALDH1A1MEN1KMT2AGFER
SCHEMBL4884915 0.73 PGR (0.52) ALDH1A1GFERGAASMN1; SMN2CA1
SCHEMBL549486 0.72 MEN1 (0.44) KDM4EALDH1A1MEN1KMT2AGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255240-A1 Sulfonamide Derivatives NOVO NORDISK A/S (DK) 2008-10-16 US disclosed
EP-1756025-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2007-02-28 EP disclosed
WO-2005105712-A1 SULFONAMIDE DERIVATIVES NOVO NORDISK A/S (DK) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255240-A1 Sulfonamide Derivatives FABP4, SQOR, CS KDM4E 854/4885ALDH1A1 1601/4885MEN1 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.